论文部分内容阅读
发展治疗内脏利什曼病的新药已有明显进展,对传统的一线和二线治疗药物亦有更深地了解。五价锑(葡萄糖酸锑钠和甲基葡萄糖胺锑) 在许多地区,病人对五价锑的抗性不断增加。治疗前杜氏利什曼原虫的分离株对五价锑的敏感性差异很大,其抗药性可能由于以往不当的疗程所引起。WHO的标准显示对五价锑的无反应性正在增加,从而推荐20mg/kg·d剂量的五价锑至少要用20天。在印度,原发的对五价锑抗性的病人约占病例
The development of new drugs for the treatment of visceral leishmaniasis has made significant progress, as well as a better understanding of traditional first-line and second-line therapies. Pentavalent antimony (antimony gluconate and antimony methylglucamine) In many areas, the patient’s resistance to pentavalent antimony is increasing. The susceptibility of isolates of Leishmania donovani before treatment to pentavalent antimony varied widely, and their resistance may be due to improper previous treatment. The WHO standard shows that there is an increase in the non-responsiveness to pentavalent antimony, recommending that a dose of 20 mg / kg · d of pentavalent antimony be used for at least 20 days. In India, the primary case of resistance to pentavalent antimony accounted for about cases